Radiation schedule study for Merkel cell skin cancer
Part of Cancer, Infections clinical trials.
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your doctor) have confirmed Merkel cell carcinoma (MCC) from a biopsy or other test.
- There is no evidence the cancer has spread to distant organs on exam and imaging scans.
- You must be at least 18 years old.
- Your planned treatment is either radiation to the primary tumor after surgery within 4 months, or radiation to lymph nodes after specific lymph node surgery/testing within 4 months.
- You cannot be currently pregnant, and you must use effective birth control during the study (and for men, also for 6 months after radiation ends).
- You should be well enough to do daily activities (ECOG score 0 to 3).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests the combination of pembrolizumab (an immunotherapy) with standard chemotherapy (cisplatin or carboplatin plus etoposide) in people with advanced Merkel cell carcinoma who haven't had treatment before. The goal is to see if this combination improves outcomes.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This study looks for Merkel cell carcinoma cells in the blood before and after surgery (and/or radiation). It may help researchers understand how these cells change with treatment.
This trial tests combining two drugs—ASTX727 (an oral pill) and retifanlimab (an immunotherapy)—for people with advanced Merkel cell carcinoma that has grown despite previous immunotherapy. The goal is to see if this combination can work better than previous treatments.
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.